Exact Mass: 425.2575600000001

D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2330 Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2]. Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2].

Diprenorphine

D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist Same as: D07863

Nafoxidine

1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine

C29H31NO2 (425.2354666)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent

LysoPE(14:0/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-(tetradecanoyloxy)propoxy]phosphinic acid

LysoPE(14:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(14:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

LysoPE(0:0/14:0)

(2-aminoethoxy)[(2R)-3-hydroxy-2-(tetradecanoyloxy)propoxy]phosphinic acid

LysoPE(0:0/14:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/14:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

M2 di-hydroxylated metabolite

2-(1-{1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl}-4-hydroxy-1H-indol-6-yl)-2-hydroxy-N-methylethanimidic acid

C24H28FN3O3 (425.211459)

M2 di-hydroxylated metabolite is a metabolite of saquinavir. Saquinavir is an antiretroviral drug used in HIV therapy. It falls in the protease inhibitor class. Two formulations have been marketed: a hard-gel capsule formulation of the mesylate, with trade name Invirase, which requires combination with ritonavir to increase the saquinavir bioavailability; a soft-gel capsule formulation of saquinavir, with trade name Fortovase. Both formulations are generally used as a component of highly active antiretroviral therapy (HAART). (Wikipedia)

(6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine

3-[(15-carboxypentadeca-6,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6Z,8Z)-hexadeca-6,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(4E,6Z)-Hexadeca-4,6-dienedioylcarnitine

3-[(15-carboxypentadeca-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (4E,6Z)-hexadeca-4,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(6E,9E)-Hexadeca-6,9-dienedioylcarnitine

3-[(15-carboxypentadeca-6,9-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(6E,9E)-Hexadeca-6,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6E,9E)-hexadeca-6,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,9E)-Hexadeca-6,9-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E,9E)-Hexadeca-6,9-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(7Z,13Z)-hexadeca-7,13-dienedioylcarnitine

3-[(15-carboxypentadeca-7,13-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (7Z,13Z)-hexadeca-7,13-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine

3-[(15-carboxypentadeca-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z)-hexadeca-4,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(12E,14E)-hexadeca-12,14-dienedioylcarnitine

3-[(15-carboxypentadeca-12,14-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(12E,14E)-Hexadeca-12,14-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (12E,14Z)-hexadeca-12,14-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12E,14E)-Hexadeca-12,14-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12E,14E)-Hexadeca-12,14-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

N-Docosahexaenoyl Proline

1-(docosa-4,7,10,13,16,19-hexaenoyl)pyrrolidine-2-carboxylic acid

C21H27N7O3 (425.21752720000006)

N-docosahexaenoyl proline belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Proline. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Proline is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Proline is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R)-

Diprenorphine

3-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol

Gly-pro-arg-pro

1-(2-{[1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-5-[(diaminomethylidene)amino]pentanoyl)pyrrolidine-2-carboxylic acid

Jervine

5-hydroxy-2,3,6,15-tetramethyl-3a,4,5,6,7,7a-hexahydro-3H-spiro[furo[3,2-b]pyridine-2,14-tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadecane]-7,15-dien-17-one

Piriprost

5-[5-hydroxy-4-(3-hydroxyoct-1-en-1-yl)-1-phenyl-1H,4H,5H,6H-cyclopenta[b]pyrrol-2-yl]pentanoic acid

C21H32ClN3O4 (425.20812220000005)

Revexepride

4-Amino-5-chloro-N-{[3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl}-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboximidate

Jervine

(2R,3S,3R,3aS,6S,6aS,6bS,7aR,11aS,1 1bR)-2,3,3a,4,4,5,6,6,6a,6b,7,7,7a,8,11a,11b-hexad ecahydro-3-hydroxy-3,6,10,11b-tetramethyl-Spiro[9H -benzo[a]fluorene-9,2(3H)-furo[3,2-b]pyridin]-11(1 H)-one

Jervine is a member of piperidines. Jervine is a natural product found in Veratrum stamineum, Veratrum grandiflorum, and other organisms with data available. Jervine is a steroidal alkaloid with molecular formula C27H39NO3 which is derived from the Veratrum plant genus. Similar to cyclopamine, which also occurs in the Veratrum genus, it is a teratogen implicated in birth defects when consumed by animals during a certain period of their gestation. D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2]. Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2].

Brachystamide D|brachystamide-D|N-isobutyl-16-(3,4-methylenedioxyphenyl)-2E,4E,15E-hexadecatrienamide|pergumidiene

hyatelactam

C22H35NO7 (425.24134000000004)

9-(2-amino-3-(4-O-methyl-alpha-rhamnopyranosyloxy)phenyl)nonanoic acid

(23R)-17,23-Epoxy-3beta-hydroxy-(13alphaH(?)-veratra-5,12(14)-dien-11-on|(23R)-17,23-epoxy-3beta-hydroxy-(13alphaH(?)-veratra-5,12(14)-dien-11-one|jervine|jervine sulfate

Asn Arg His

Ile Phe Phe

Prostaglandin D2 serinol amide

N-[(2-hydroxy-1-hydroxymethyl)ethyl]-11-oxo-9α,15S-dihydroxy-prosta-5Z,13E-dien-1-amide

histidylasparagylarginine

Prostaglandin E2 serinol amide

N-[(2-hydroxy-1-hydroxymethyl)ethyl]-9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-amide

His Arg Asn

Phe Ile Phe

asparagylhistidylarginine

Arg Asn His

Arg His Asn

VERALODINE

NCGC00160229-01!VERALODINE

C27H39NO3_(3beta,9xi,22S,23R)-3-Hydroxy-17,23-epoxyveratraman-11-one

NCGC00380997-01_C27H39NO3_(3beta,9xi,22S,23R)-3-Hydroxy-17,23-epoxyveratraman-11-one

(3S,3R,3aS,6S,6aS,6bS,7aR,9R,11bR)-3-hydroxy-3,6,10,11b-tetramethylspiro[1,2,3,4,6,6a,6b,7,8,11a-decahydrobenzo[a]fluorene-9,2-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-11-one

1-tetradecanoyl-sn-glycero-3-phosphoethanolamine

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine

Ala Ala His Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

Ala Ala Lys His

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

Ala His Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]propanamido]hexanoic acid

Ala His Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]propanoic acid

Ala Lys Ala His

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]propanamido]-3-(1H-imidazol-4-yl)propanoic acid

Ala Lys His Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]propanoic acid

Gly Gly His Arg

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

Gly Gly Arg His

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

Gly His Gly Arg

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanoic acid

Gly His Arg Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]acetic acid

Gly Pro Pro Arg

(2S)-2-{[(2S)-1-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

Gly Pro Arg Pro

(2S)-1-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

Gly Arg Gly His

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]acetamido}-3-(1H-imidazol-4-yl)propanoic acid

Gly Arg His Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]acetic acid

Gly Arg Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

His Ala Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]propanamido]hexanoic acid

His Ala Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]hexanamido]propanoic acid

His Gly Gly Arg

(2S)-2-(2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}acetamido)-5-carbamimidamidopentanoic acid

His Gly Arg Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanamido]acetic acid

His Lys Ala Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]propanamido]propanoic acid

His Arg Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]acetamido}acetic acid

Leu Phe Phe

Lys Ala Ala His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]propanamido]-3-(1H-imidazol-4-yl)propanoic acid

Lys Ala His Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]propanoic acid

Lys His Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-imidazol-4-yl)propanamido]propanamido]propanoic acid

Asn His Arg

Phe Phe Leu

Asn Pro Pro Val

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

Asn Pro Val Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

Asn Val Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Pro Gly Pro Arg

(2S)-5-carbamimidamido-2-{[(2S)-1-{2-[(2S)-pyrrolidin-2-ylformamido]acetyl}pyrrolidin-2-yl]formamido}pentanoic acid

Pro Gly Arg Pro

(2S)-1-[(2S)-5-carbamimidamido-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}pentanoyl]pyrrolidine-2-carboxylic acid

Pro Asn Pro Val

(2S)-2-{[(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

Pro Asn Val Pro

(2S)-1-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

Pro Pro Gly Arg

(2S)-5-carbamimidamido-2-(2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetamido)pentanoic acid

Phe Leu Phe

Pro Pro Asn Val

(2S)-2-[(2S)-3-carbamoyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}propanamido]-3-methylbutanoic acid

Pro Pro Arg Gly

2-[(2S)-5-carbamimidamido-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}pentanamido]acetic acid

Pro Pro Val Asn

(2S)-3-carbamoyl-2-[(2S)-3-methyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}butanamido]propanoic acid

Pro Arg Gly Pro

(2S)-1-{2-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanamido]acetyl}pyrrolidine-2-carboxylic acid

Pro Arg Pro Gly

2-{[(2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanoyl]pyrrolidin-2-yl]formamido}acetic acid

Pro Val Asn Pro

(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]propanoyl]pyrrolidine-2-carboxylic acid

Pro Val Pro Asn

(2S)-3-carbamoyl-2-{[(2S)-1-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanoyl]pyrrolidin-2-yl]formamido}propanoic acid

Arg Gly Gly His

(2S)-2-(2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}acetamido)-3-(1H-imidazol-4-yl)propanoic acid

Arg Gly His Gly

2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-(1H-imidazol-4-yl)propanamido]acetic acid

Arg Gly Pro Pro

(2S)-1-{[(2S)-1-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetyl}pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Arg His Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]acetamido}acetic acid

Arg Pro Gly Pro

(2S)-1-(2-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid

Arg Pro Pro Gly

2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetic acid

His Asn Arg

Phe Phe Ile

Val Asn Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Val Pro Asn Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

Val Pro Pro Asn

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

Divaleroylphosphatidylcholine

3,5,9-Trioxa-4-phosphatetradecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxopentyl)oxy]-, inner salt, 4-oxide, (R)-

PC(5:0/5:0)[U]

3,5,9-Trioxa-4-phosphatetradecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxopentyl)oxy]-, inner salt, 4-oxide

PC(O-6:0/O-6:0)

3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 7-(hexyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)-

PC(O-6:0/O-6:0)[U]

3,5,9-Trioxa-4-phosphapentadecan-1-aminium, 7-(hexyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide

PC(11:0/0:0)

Undecanoin, 1-mono-, 3-(dihydrogen phosphate), monoester with choline hydroxide inner salt, L-

PC(11:0/0:0)[U]

3,5,9-Trioxa-4-phosphaeicosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide

PC(0:0/11:0)[U]

3,5,8-Trioxa-4-phosphanonadecan-1-aminium, 4-hydroxy-7-(hydroxymethyl)-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide

PC(O-12:0/0:0)[U]

3,5,9-Trioxa-4-phosphaheneicosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide

PE(14:0/0:0)

Tetradecanoic acid, 3-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-hydroxypropyl ester, (R)-

LPE(14:0)

1-Hydroxy-2-myristoyl-sn-glycero-3-phosphoethanolamine

PGD2-dihydroxypropanylamine

N-(1,3-dihydroxypropan-2-yl)-9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoyl amine

PGE2-dihydroxypropanylamine

N-(1,3-dihydroxypropan-2-yl)-9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoyl amine

NA 27:8;O

(5E,7E)-8-[(3aS,4R,5R,7aR)-4-[(1Z,3E)-5-oxo-5-(2-methyl-butylamino)-penta-1,3-dienyl]-2,3,3a,4,5,7a-hexahydro-1H-inden-5-yl]octa-5,7-dienoic acid

PC 10:0

1,2-divaleryl-sn-glycero-3-phosphocholine

LPC 11:0

1-undecanoyl-sn-glycero-3-phosphocholine

LPE 14:0

Tetradecanoic acid, 3-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-hydroxypropyl ester, (R)-

C21H40NNaO4S (425.2575600000001)

sodium 2-[methyloleoylamino]ethane-1-sulphonate

2-(4,6-Diphenyl-1,3,5-triazin-2-yl)-5-[(hexyl)oxy]-phenol

C27H27N3O2 (425.2103162)

Piriprost

5-[5-hydroxy-4-[(E)-3-hydroxyoct-1-enyl]-1-phenyl-5,6-dihydro-4H-cyclopenta[b]pyrrol-2-yl]pentanoic acid

C21H27N7O3 (425.21752720000006)

D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors C471 - Enzyme Inhibitor > C1322 - Lipooxygenase Inhibitor C78568 - Prostaglandin Analogue

(S)-BnCH2-PyBox, (S,S)-2,6-Bis(4-benzylmethyl-2-oxazolin-2-yl)pyridine

C27H27N3O2 (425.2103162)

GSK690693

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C155764 - AKT Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3]. GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3].

2-(((3-(Aziridin-1-yl)propanoyl)oxy)methyl)-2-ethylpropane-1,3-diyl bis(3-(aziridin-1-yl)propanoate)

C21H35N3O6 (425.25257300000004)

GPRP

hexadecyl phosphate, 2-(2-hydroxyethylamino)ethanol

N-Boc-4-azido-L-hoMoalanine (dicyclohexylaMMoniuM) salt

C21H39N5O4 (425.3001894)

Diproteverine

C25H40NNaO3 (425.2905730000001)

Sodium N-hexadecanoyl-L-phenlyalaninate

Tetraisoamylammonium iodide

1-Butanaminium,3-methyl-N,N,N-tris(3-methylbutyl)-, iodide (1:1)

C20H44IN (425.2518334)

Bis(3-triethoxysilylpropyl)amine

C18H43NO6Si2 (425.26287780000007)

Tetrapentylammonium iodide

N,N,N-Tripentyl-1-pentanaminium iodide

C20H44IN (425.2518334)

sodium N-meethyl, N-oleoy-lamino ethyl salfonate

C21H40NaNO4S (425.2575600000001)

(1R,3S,4S)-3-[6-(5,5-DiMethyl-1,3,2-dioxaborinan-2-yl)-1H-benziMidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-diMethylethyl ester

C23H32BN3O4 (425.2485742)

1,3-Bis(2,6-diisopropylphenyl)-1,3,2-diazaphospholidine 2-Oxide

C26H38N2OP+ (425.2721608)

bis-(2,2,6,6-Tetramethyl-3,5-heptanedionato)cobalt(II)

C22H38CoO4 (425.2101928)

carfenazine

C24H31N3O2S (425.2136866)

C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent

Adodato

C18H31N7O3S (425.22089760000006)

(R)-2,3-Bis(pentanoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate

1-Dodecylpropanediol-3-phosphocholine

Diprenorphine

3-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol

C21H27N7O3 (425.21752720000006)

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R)-

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine

2-acyl-sn-glycero-3-phosphoethanolamine (n-C14:0)

1-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]pyrrolidine-2-carboxylic acid

(6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine

(4E,6Z)-Hexadeca-4,6-dienedioylcarnitine

(6E,9E)-Hexadeca-6,9-dienedioylcarnitine

(4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine

(7Z,13Z)-hexadeca-7,13-dienedioylcarnitine

(12E,14E)-hexadeca-12,14-dienedioylcarnitine

C22H36NO5P-2 (425.23309760000006)

Daphmanidins E

C25H31NO5 (425.2202116)

N-arachidonoylethanolamine phosphate(2-)

3,9beta-Hydroxy-22alpha,23alpha-epoxy-9(10)-seco-solanida-1,3,5(10)-triene, (rel)-

A natural product found in Solanum campaniforme.

(9S,11R,15R,17S)-23-Methoxy-25-azatetracyclo[18.3.1.12,6.111,15]hexacosa-1(23),2,4,6(26),20(24),21-hexaene-3,9,17-triol